Stabilized HIV-1 envelope glycoprotein trimers for vaccine use

Current Opinion in HIV and AIDS

Volumn 12, Issue 3, 2017, Pages 241-249

  Medina Ramírez, Max ^a   Sanders, Rogier W ^a,b   Sattentau, Quentin J ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Broadly neutralizing antibodies; chemical cross linking; HIV 1 envelope glycoproteins; mutagenesis; soluble trimers; stabilization; trimer structure

Indexed keywords

B LYMPHOCYTE RECEPTOR; ENVELOPE PROTEIN; GLYCOPROTEIN; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY; VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; CONFORMATIONAL TRANSITION; CROSS LINKING; DRUG STABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; GENETICS; HIV INFECTIONS; IMMUNOLOGY; PROTEIN STABILITY; VIROLOGY;

AIDS VACCINES; ANIMALS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN STABILITY;

EID: 85013672240     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000363     Document Type: Review

References (115)

1. Mascola J.R., Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010; 28:413-444.
2. Moore JP, Cao Y, Qing L, et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, their neutralization is not predicted by studies with monomeric gp120. J Virol 1995; 69:101-109.
3. Moore JP, Ho DD. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells. AIDS 1995; 9 (Suppl A):S117-S136.
4. Moore JP. HIV vaccines. Back to primary school. Nature 1995; 376:115.
5. Moore JP, Ho DD. HIV neutralization: The consequence of viral adaptation to growth on transformed T cells. AIDS 1995; 9 (Suppl A):S117-S136.
6. Parren PW, Wang M, Trkola A, et al. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J Virol 1998; 72:10270-10274.
7. Sattentau QJ, Moore JP. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 1995; 182:185-196.
8. Fouts TR, Binley JM, Trkola A, et al. Neutralization of the human immunodeficiency virus type 1 primary isolate JRFL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 1997; 71:2779-2785.
9. Parren PW, Mondor I, Naniche D, et al. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol 1998; 72:3512-3519.
10. Burton DR, Saphire EO, Parren PW. A model for neutralization of viruses based on antibody coating of the virion surface. Curr Top Microbiol Immunol 2001; 260:109-143.
11. Klasse PJ, Sattentau QJ. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 2002; 83:2091-2108.
12. Ugolini S, Mondor I, Parren PW, et al. Inhibition of virus attachment to CD4\+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med 1997; 186:1287-1298.
13. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4\+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-673.
14. Poignard P, Fouts T, Naniche D, et al. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. J Exp Med 1996; 183:473-484.
15. Ruprecht CR, Krarup A, Reynell L, et al. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med 2011; 208:439-454.
16. Haim H, Salas I, McGee K, et al. Modeling virus-A nd antibody-specific factors to predict human immunodeficiency virus neutralization efficiency. Cell Host Microbe 2013; 14:547-558.
17. Lee JH, Leaman DP, Kim AS, et al. Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nat Commun 2015; 6:8167.
18. Julien JP, Sok D, Khayat R, et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 2013; 9:e1003342.
19. Sok D, van Gils MJ, Pauthner M, et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. PNAS 2014; 111:17624-17629.
20. Galimidi RP, Klein JS, Politzer MS, et al. Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell 2015; 160:433-446.
21. Yang X, Farzan M, Wyatt R, Sodroski J. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2000; 74:5716-5725.
22. Yang X, Florin L, Farzan M, et al. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J Virol 2000; 74:4746-4754.
23. Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 2001; 75:1165-1171.
24. Forsell MN, Schief WR, Wyatt RT. Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr Opin HIV AIDS 2009; 4:380-387.
25. Grundner C, Li Y, Louder M, et al. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 2005; 331:33-46.
26. Nkolola JP, Peng H, Settembre EC, et al. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J Virol 2010; 84:3270-3279.
27. Sanders RW, van Gils MJ, Derking R, et al. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 2015; 349:aac4223.
28. Ringe RP, Sanders RW, Yasmeen A, et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci USA 2013; 110:18256-18261.
29. Yasmeen A, Ringe R, Derking R, et al. Differential binding of neutralizing and nonneutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, monomeric subunits. Retrovirology 2014; 11:41.
30. Ringe RP, Yasmeen A, Ozorowski G, et al. Influences on the design and purification of soluble, recombinant native-like HIV-1 envelope glycoprotein trimers. J Virol 2015; 89:12189-12210.
31. Sanders RW, Moore JP. Native-like env trimers as a platform for hiv-1 vaccine design. Imm Rev 2017; 275:161-182.
32. Kovacs JM, Nkolola JP, Peng H, et al. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci USA 2012; 109:12111-12116.
33. de Taeye SW, Moore JP, Sanders RW. HIV-1 envelope trimer design and immunization strategies to induce broadly neutralizing antibodies. Trends Immunol 2016; 37:221-232.
34. Lyumkis D, Julien JP, de Val N, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013; 342:1484-1490.
35. Kong L, Sattentau QJ. Antigenicity and immunogenicity in HIV-1 antibodybased vaccine design. J AIDS Clin Res 2012; S8:3.
36. Verkoczy L, Kelsoe G, Moody MA, Haynes BF. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol 2011; 23:383-390.
37. Verkoczy L, Kelsoe G, Haynes BF. HIV-1 envelope gp41 broadly neutralizing antibodies: Hurdles for vaccine development. PLoS Pathog 2014; 10:e1004073.
38. Doria-Rose NA, Schramm CA, Gorman J, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014; 509:55-62.
39. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012; 30:423-433.
40. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466-470.
41. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 2005; 21:171-189.
42. Huang CC, Tang M, Zhang MY, et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005; 310:1025-1028.
43. Jardine J, Julien JP, Menis S, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013; 340:711-716.
44. Jardine JG, Kulp DW, Havenar-Daughton C, et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 2016; 351:1458-1463.
45. Sok D, Briney B, Jardine JG, et al. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science 2016; 353:1557-1560.
46. Chen L, Kwon YD, Zhou T, et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009; 326:1123-1127.
47. Pancera M, Zhou T, Druz A, et al. Structure and immune recognition of trimeric prefusion HIV-1 Env. Nature 2014; 514:455-461.
48. Kwon YD, Pancera M, Acharya P, et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol 2015; 22:522-531.
49. Binley JM, Ban YE, Crooks ET, et al. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 2010; 84:5637-5655.
50. Kong L, Sheppard NC, Stewart-Jones GB, et al. Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. J Mol Biol 2010; 403:131-147.
51. Kang YK, Andjelic S, Binley JM, et al. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 2009; 27:5120-5132.
52. Beddows S, Franti M, Dey AK, et al. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 2007; 360:329-340.
53. Beddows S, Schulke N, Kirschner M, et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2005; 79: 8812-8827.
54. Sanders RW, Derking R, Cupo A, et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP. 664 gp140, expresses multiple epitopes for broadly neutralizing but not nonneutralizing antibodies. PLoS Pathog 2013; 9:e1003618.
55. Klasse PJ, Depetris RS, Pejchal R, et al. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol 2013; 87:9873-9885.
56. Khayat R, Lee JH, Julien JP, et al. Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol 2013; 87:9865-9872.
57. Julien JP, Cupo A, Sok D, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013; 342:1477-1483.
58. Stewart-Jones GB, Soto C, Lemmin T, et al. Trimeric HIV-1-env structures define glycan shields from clades A, B, G. Cell 2016; 165:813-826.
59. Gristick HB, von Boehmer L, West AP Jr, et al. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat Struct Mol Biol 2016; 23:906-915.
60. Kong R, Xu K, Zhou T, et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 2016; 352:828-833.
61. Garces F, Lee JH, de Val N, et al. Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity 2015; 43:1053-1063.
62. Lee JH, Ozorowski G, Ward AB. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 2016; 351: 1043-1048.
63. Sanders RW, Vesanen M, Schuelke N, et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002; 76:8875-8889.
64. Sanders RW, Moore JP. HIV: A stamp on the envelope. Nature 2014; 514:437-438.
65. Garces F, Sok D, Kong L, et al. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 2014; 159:69-79.
66. van Gils MJ, van den Kerkhof TL, Ozorowski G, et al. An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat Microbiol 2016; 2:16199.
67. Sharma SK, de Val N, Bale S, et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep 2015; 11:539-550.
68. Guenaga J, Dubrovskaya V, de Val N, et al. Structure-guided redesign increases the propensity of HIV Env to generate highly stable soluble trimers. J Virol 2015; 90:2806-2817.
69. Kong L, He L, de Val N, et al. Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nat Commun 2016; 7:12040.
70. Steichen JM, Kulp DW, Tokatlian T, et al. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity 2016; 45:483-496.
71. Klasse PJ, LaBranche CC, Ketas TJ, et al. Sequential and simultaneous immunization of rabbits with HIV-1 envelope glycoprotein SOSIP. 664 trimers from clades A, B and C. PLoS Pathog 2016; 12:e1005864.
72. McCoy LE, van Gils MJ, Ozorowski G, et al. Holes in the glycan shield of the native HIV envelope are a target of trimer-elicited neutralizing antibodies. Cell Rep 2016; 16:2327-2338.
73. Sattentau QJ, Moore JP. Conformational changes induced in the human immunodeficiency virus envelope glycoproteins by soluble CD4 binding. J Exp Med 1991; 174:407-415.
74. Signoret N, Poignard P, Blanc D, Sattentau QJ. Human and simian immunodeficiency viruses: Virus-receptor interactions. Trends Microbiol 1993; 1:328-333.
75. Harris A, Borgnia MJ, Shi D, et al. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci USA 2011; 108:11440-11445.
76. Scharf L, Wang H, Gao H, et al. Broadly neutralizing antibody 8ANC195 recognizes closed and open states of HIV-1 env. Cell 2015; 162:1379-1390.
77. de Taeye SW, Ozorowski G, Torrents dlP, et al. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of nonneutralizing epitopes. Cell 2015; 163:1702-1715.
78. Guttman M, Cupo A, Julien JP, et al. Antibody potency relates to the ability to recognize the closed, prefusion form of HIV Env. Nat Commun 2015; 6:6144.
79. Munro JB, Gorman J, Ma X, et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 2014; 346: 759-763.
80. Guttman M, Garcia NK, Cupo A, et al. CD4-induced activation in a soluble HIV-1 Env trimer. Structure 2014; 22:974-984.
81. Munro JB, MothesW. Structure and dynamics of the native HIV-1 Env trimer. J Virol 2015; 89:5752-5755.
82. McGuire AT, Dreyer AM, Carbonetti S, et al., HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 2014; 346:1380-1383.
83. Rappuoli R. Toxin inactivation and antigen stabilization-2 different uses of formaldehyde. Vaccine 1994; 12:579-581.
84. Wilton T, Dunn G, Eastwood D, et al. Effect of formaldehyde inactivation on poliovirus (vol 88, pg 11955, 2014). J Virol 2014; 88:13928-113928.
85. Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 2015; 14:167-182.
86. Fan YC, Chiu HC, Chen LK, et al. Formalin inactivation of Japanese encephalitis virus vaccine alters the antigenicity and immunogenicity of a neutralization epitope in envelope protein domain III. PLoS Negl Trop Dis 2015; 9:e0004167.
87. Metz B, Kersten GFA, Baart GJE, et al. Identification of formaldehydeinduced modifications in proteins: Reactions with insulin. Bioconjug Chem 2006; 17:815-822.
88. Migneault I, Dartiguenave C, Bertrand MJ, Waldron KC. Glutaraldehyde: Behavior in aqueous solution, reaction with proteins, application to enzyme crosslinking. Biotechniques 2004; 37:790-796; 798-802.
89. Sattentau QJ. Conservation of HIV-1 gp120 neutralizing epitopes after formalin inactivation. AIDS 1995; 9:1383-1385.
90. Schiffner T, Kong L, Duncan C, et al. Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. J Virol 2013; 87:10163-10172.
91. Yuan W, Bazick J, Sodroski J. Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker. J Virol 2006; 80: 6725-6737.
92. Haim H, Salas I, Sodroski J. Proteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibility. J Virol 2012; 87:1884-1889.
93. Leaman DP, Lee JH, Ward AB, Zwick MB. Immunogenic display of purified chemically cross-linked HIV-1 spikes. J Virol 2015; 89:6725-6745.
94. Schiffner T, de Val N, Russell RA, et al. Chemical cross-linking stabilizes native-like HIV-1 envelope glycoprotein trimer antigens. J Virol 2015; 90:813-828.
95. Feng Y, Tran K, Bale S, et al. Thermostability of well ordered HIV spikes correlates with the elicitation of autologous tier 2 neutralizing antibodies. PLoS Pathog 2016; 12:e1005767.
96. Bonsignori M, Alam SM, Liao HX, et al. HIV-1 antibodies from infection and vaccination: Insights for guiding vaccine design. Trends Microbiol 2012; 20:532-539.
97. Haynes BF. New approaches to HIV vaccine development. Curr Opin Immunol 2015; 35:39-47.
98. Haynes BF, Bradley T. Broadly neutralizing antibodies and the development of vaccines. JAMA 2015; 313:2419-2420.
99. Haynes BF, Fleming J, St Clair EW, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308:1906-1908.
100. Hraber P, Korber B, Wagh K, et al. Longitudinal antigenic sequences and sites from intra-host evolution (LASSIE) identifies immune-selected HIV variants. Viruses 2015; 7:5443-5475.
101. Xiao X, ChenW, Feng Y, Dimitrov DS. Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses 2009; 1:802-817.
102. Xiao X, Chen W, Feng Y, et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 2009; 390: 404-409.
103. Zhou T, Georgiev I, Wu X, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329:811-817.
104. Sliepen K, Medina-Ramirez M, Yasmeen A, et al. Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. Virology 2015; 486:116-120.
105. Jardine JG, Ota T, Sok D, et al. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 2015; 349:156-161.
106. McGuire AT, Gray MD, Dosenovic P, et al. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat Commun 2016; 7:10618.
107. McGuire AT, Hoot S, Dreyer AM, et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 2013; 210:655-663.
108. Tian M, Cheng C, Chen X, et al. Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires. Cell 2016; 166:1471-1484; e1418.
109. Medina-Ramirez M, Garces F, Escolano Amelia, et al. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. Submitted for publication.
110. Briney B, Sok D, Jardine JG, et al. Tailored immunogens direct affinity maturation toward HIV neutralizing antibodies. Cell 2016; 166:1459-1470; e1411.
111. Escolano A, Steichen JM, Dosenovic P, et al. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice. Cell 2016; 166:1445-1458; e1412.
112. Kong L, Ju B, Chen Y, et al. Key gp120 glycans pose roadblocks to the rapid development of VRC01-class antibodies in an HIV-1-infected Chinese donor. Immunity 2016; 44:939-950.
113. Lynch RM, Wong P, Tran L, et al. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J Virol 2015; 89:4201-4213.
114. McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342:592-598.
115. Joyce MG, Zhang B, Ou L, et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol 2016; 23:811-820.